Table 2.
Clinical features of neonates with RT-PCR proven SARS-CoV-2 infection and admitted to hospital
| Complaints | n (%) | |
|---|---|---|
| Asymptomatic | 19 (10.8) | |
| Fever | 113 (64.2) | |
| Only fever | 45 (25.6) | |
| + Any respiratory symptoms | 23 (13.1) | |
| + Any GIS symptoms | 23 (13.1) | |
| + Respiratory and GIS symptoms | 11 (6.2) | |
| + Somnolence/irritability | 5 (2.8) | |
| Feeding intolerance | 45 (25.6) | |
| Cough | 38 (21.6) | |
| Tachypnea | 33 (18.8) | |
| Retractions | 22 (12.5) | |
| Diarrhea | 14 (8) | |
| Rhinorrhea | 14 (8) | |
| Somnolence/Irritability | 13 (7.4) | |
| Rash | 3 (1.7) | |
| Hospitalization (n, %) | 170 (96.6) | |
| Chest CT (n, %) | 8 (4.5) | |
| Groundglass/consolidation | 4 (2.2) | |
| Complications | ||
| Myocarditis (n, %) | 10 (5.7) | |
| DIC (n, %) | 1 (0.6) | |
| Multiple organ dysfunction (n, %) | 1 (0.6) | |
| Feeding type | ||
| Breastfeeding with PPE (n, %) | 31 (17.6) | |
| Expressed milk with PPE (n, %) | 90 (51.1) | |
| Breastfeeding without PPE (n, %) | 13 (7.4) | |
| Formula (n, %) | 42 (23.9) | |
| Treatment | Duration (median, min–max) | |
| No treatment (n, %) | 69 (39.2) | |
| Antibiotic treatment (n, %) (days) | 95 (54) | 7 (2–26) |
| Azithromycin treatment (n, %), (days) | 29 (16.5) | 5 (1–10) |
| Oseltamivir treatment (n, %), (days) | 15 (8.5) | 5 (5–7) |
| Respiratory support | ||
| Oxygen supplementation (n, %) (h) | 47 (26.7) | 58 (8–504) |
| nCPAP requirement (n, %) (h) | 17 (9.6) | 47 (6–456) |
| Mechanical ventilation (n, %) (h) | 8 (4.5) | 47.5 (5–494) |
| Hospitalization (days) | 9 (1–70) | |
GIS gastrointestinal system, CT computed tomography, DICdisseminated intravascular coagulation, PPE personal protective equipment, nCPAP nasal continuous airway pressure